By Nana O 
Northwestern University researchers have unveiled a groundbreaking laboratory-developed model of the human spinal cord, marking a significant leap forward in the study of spinal cord injury (SCI) and the evaluation of potential regenerative treatments. This advanced organoid system, derived from human stem cells, has demonstrated an unprecedented ability to replicate the complex biological consequences of SCI, paving the way for more effective and targeted therapeutic development.
A New Era for Spinal Cord Injury Research
The newly developed human spinal cord organoids, meticulously engineered by a team led by Professor Samuel I. Stupp, represent the most sophisticated in vitro model to date for simulating the devastating effects of spinal cord trauma. For the first time, scientists have been able to observe and analyze key pathological hallmarks of SCI within a human tissue environment, including widespread cell death, intense inflammation, and the formation of glial scars. These scars, a dense network of glial cells, act as a formidable physical and chemical barrier, impeding the natural regeneration of damaged nerve fibers.
The significance of this development cannot be overstated. Spinal cord injuries, often resulting from accidents such as car crashes, falls, or sports-related incidents, can lead to profound and permanent loss of motor and sensory function, profoundly impacting the lives of millions globally. Current treatment options are limited, and the path to meaningful recovery remains a formidable challenge, largely due to the inherent inability of the central nervous system to effectively repair itself. The creation of this human-specific organoid model offers a critical new platform to understand these repair failures and, crucially, to test novel interventions with a higher degree of translational relevance than previously possible.
Replicating the Devastation of Injury
The Northwestern team’s research, published on February 11th in the prestigious journal Nature Biomedical Engineering, details how these miniature spinal cord tissues were cultivated over several months. The process involved guiding induced pluripotent stem cells to develop into complex spinal cord structures, containing not only neurons but also astrocytes, a crucial type of glial cell. A key innovation in this model was the incorporation of microglia, the resident immune cells of the central nervous system. This inclusion was vital, as microglia play a pivotal role in the inflammatory cascade that follows SCI, and their absence in previous models limited the accuracy of injury simulation.
"It’s kind of a pseudo-organ," explained Professor Stupp, the study’s senior author and a distinguished figure in regenerative materials science at Northwestern. "We were the first to introduce microglia into a human spinal cord organoid, so that was a huge accomplishment. It means that our organoid has all the chemicals that the resident immune system produces in response to an injury. That makes it a more realistic, accurate model of spinal cord injury."
To induce injury within these sophisticated organoids, researchers employed two distinct methods that mimic common human SCI scenarios. Some organoids were precisely cut with a scalpel, simulating the direct tissue damage that can occur during surgical procedures or severe lacerations. Others were subjected to a compressive contusion, a more diffuse form of trauma that mirrors the impact of events like severe car accidents or significant falls.
Following these simulated injuries, the organoids exhibited a cascade of pathological responses mirroring those observed in human patients. Extensive cell death was detected, indicating the immediate impact of trauma on neural tissue. Perhaps most critically, the formation of glial scars was observed. The researchers were able to differentiate between the astrocytes that constitute healthy spinal cord tissue and the significantly enlarged and densely packed astrocytes characteristic of glial scar formation. Furthermore, the production of chondroitin sulfate proteoglycans (CSPGs) was confirmed. CSPGs are molecules in the nervous system known to actively inhibit nerve regeneration after injury, further contributing to the barrier effect of glial scars.
A Glimmer of Hope with "Dancing Molecules"
The true potential of this novel organoid model became apparent when the researchers introduced a promising regenerative therapy, dubbed "dancing molecules." This innovative treatment, also developed by Professor Stupp’s lab, has shown remarkable efficacy in previous animal studies, restoring movement and repairing damaged tissue. The therapy leverages the dynamic motion of supramolecular therapeutic peptides (STPs) to activate cellular repair mechanisms.
The "dancing molecules" are delivered as a liquid injection that rapidly self-assembles into a nanofiber scaffold, mimicking the extracellular matrix of the spinal cord. The key to their therapeutic power lies in their controlled molecular motion. Unlike static molecules, these STPs exhibit dynamic movement, allowing them to more effectively interact with and activate cell receptors, thereby stimulating the body’s intrinsic repair pathways.
"Given that cells themselves and their receptors are in constant motion, you can imagine that molecules moving more rapidly would encounter these receptors more often," Professor Stupp had stated previously in 2021 when the therapy was first introduced. "If the molecules are sluggish and not as ‘social,’ they may never come into contact with the cells."
The results of the treatment in the human spinal cord organoids were nothing short of dramatic. Following the application of the dancing molecules therapy to the injured organoids, significant improvements were observed. The dense glial scar tissue, which had previously formed a substantial impediment to repair, was dramatically reduced, becoming barely detectable. This reduction in scar tissue is a critical step, as it clears the way for nerve regeneration.
Crucially, the researchers also observed substantial neurite outgrowth. Neurites are the long, thread-like extensions of nerve cells, including axons, which are responsible for transmitting electrical and chemical signals between neurons. In spinal cord injuries, these axons are often severed, disrupting neural communication and leading to paralysis and loss of sensation. The observed neurite regrowth in the treated organoids signifies the potential for reconnecting these severed pathways and restoring lost function. The neurons in the organoids began to grow in more organized patterns, suggesting a restoration of neural circuitry.
Validation and Future Directions
The findings in the human organoid model strongly align with the promising results seen in previous animal studies, where a single injection of the dancing molecules therapy administered 24 hours after a severe injury enabled mice to regain mobility within four weeks. This consistency across different models provides robust validation for the therapy’s potential efficacy in humans.
"One of the most exciting aspects of organoids is that we can use them to test new therapies in human tissue," Professor Stupp emphasized. "Short of a clinical trial, it’s the only way you can achieve this objective. We decided to develop two different injury models in a human spinal cord organoid and test our therapy to see if the results resembled what we previously saw in the animal model. After applying our therapy, the glial scar faded significantly to become barely detectable, and we saw neurites growing, resembling the axon regeneration we saw in animals. This is validation that our therapy has a good chance of working in humans."
The "dancing molecules" therapy is a testament to advancements in supramolecular chemistry and regenerative medicine. It belongs to a broader category of supramolecular therapeutic peptides (STPs), which rely on the coordinated action of large molecular assemblies to interact with biological targets. Notably, the underlying concept of supramolecular therapies has found application in other areas of medicine, including current GLP-1 drugs used for weight loss and diabetes management, an area Professor Stupp’s lab explored nearly 15 years ago.
The U.S. Food and Drug Administration (FDA) has recognized the potential of this therapy by granting it Orphan Drug Designation. This designation provides incentives for the development of drugs intended to treat rare diseases or conditions, and it underscores the therapeutic promise of the dancing molecules for individuals with spinal cord injuries.
The Power of Organoid Technology
Organoids, such as the human spinal cord model developed by Northwestern, are miniature, simplified versions of organs grown in the laboratory from induced pluripotent stem cells. Despite their size, they remarkably mimic the structure, cellular diversity, and functional characteristics of their in vivo counterparts. This makes them invaluable tools for advancing scientific understanding in several key areas:
- Disease Modeling: Organoids allow researchers to study the intricate biological mechanisms underlying various diseases in a human-relevant context, providing insights that may be difficult or impossible to obtain from animal models or human patients.
- Therapeutic Testing: They serve as an ethical and cost-effective platform for screening and evaluating the efficacy and safety of potential new drugs and treatments before they proceed to human clinical trials. This accelerates the drug discovery pipeline and reduces the reliance on animal experimentation.
- Developmental Biology: Organoids offer a unique window into the complex processes of organ development, enabling scientists to study how tissues form and differentiate from stem cells.
While other research groups have successfully generated spinal cord organoids for basic biological studies, the Northwestern model distinguishes itself through its maturity and complexity, enabling it to accurately recapitulate traumatic damage. The organoids, measuring several millimeters in diameter, were sufficiently developed to sustain and model the effects of severe injury.
Addressing Chronic Injuries and Personalized Medicine
Looking ahead, the Northwestern team is committed to further refining their organoid models. A key focus for future development includes engineering organoids capable of replicating chronic spinal cord injuries. These long-standing injuries are often characterized by even more pronounced and persistent scar tissue, presenting a greater challenge for regenerative therapies. Developing models for chronic SCI will be crucial for testing treatments aimed at reversing established damage.
Furthermore, Professor Stupp envisions a future where these advanced organoids could contribute to personalized medicine. By generating implantable tissue derived from a patient’s own stem cells, the risk of immune rejection could be significantly mitigated, paving the way for more individualized and effective therapeutic strategies. This approach holds the promise of tailoring treatments to the specific biological profile of each patient, maximizing the chances of successful recovery.
The research was supported by the Center for Regenerative Nanomedicine at Northwestern University and a generous gift from the John Potocsnak Family specifically for spinal cord injury research. The collaborative efforts and dedicated funding highlight the significant scientific and societal interest in finding effective solutions for spinal cord injuries. This groundbreaking work by Northwestern scientists represents a critical step forward, offering a beacon of hope for millions affected by spinal cord injuries worldwide and accelerating the journey towards meaningful therapeutic breakthroughs.
